ABIOMED, Inc. (ABMD) Holdings Raised by Utah Retirement Systems

Utah Retirement Systems lifted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 1.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,400 shares of the medical equipment provider’s stock after buying an additional 100 shares during the period. Utah Retirement Systems’ holdings in ABIOMED were worth $1,060,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of ABIOMED by 0.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,978 shares of the medical equipment provider’s stock worth $874,000 after buying an additional 25 shares during the period. BB&T Securities LLC increased its holdings in shares of ABIOMED by 1.0% in the second quarter. BB&T Securities LLC now owns 4,154 shares of the medical equipment provider’s stock worth $595,000 after buying an additional 43 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of ABIOMED by 1.6% in the second quarter. Teacher Retirement System of Texas now owns 3,294 shares of the medical equipment provider’s stock worth $472,000 after buying an additional 51 shares during the period. Capstone Asset Management Co. increased its holdings in shares of ABIOMED by 1.1% in the second quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock worth $919,000 after buying an additional 70 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of ABIOMED by 1.2% in the first quarter. PNC Financial Services Group Inc. now owns 7,842 shares of the medical equipment provider’s stock worth $982,000 after buying an additional 95 shares during the period. Hedge funds and other institutional investors own 89.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/utah-retirement-systems-raises-stake-in-abiomed-inc-abmd/1601742.html.

A number of research analysts recently issued reports on ABMD shares. Morgan Stanley restated an “equal weight” rating and set a $140.00 price target (up previously from $135.00) on shares of ABIOMED in a report on Monday, July 10th. Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. BidaskClub downgraded ABIOMED from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Jefferies Group LLC boosted their price target on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $160.00 price target (up previously from $145.00) on shares of ABIOMED in a report on Thursday, July 27th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $158.29.

In related news, Director Eric A. Md Rose sold 23,018 shares of ABIOMED stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $151.09, for a total transaction of $3,477,789.62. Following the transaction, the director now directly owns 24,652 shares of the company’s stock, valued at $3,724,670.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Eric A. Md Rose sold 982 shares of ABIOMED stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the transaction, the director now directly owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,500 shares of company stock worth $7,603,342. Corporate insiders own 7.00% of the company’s stock.

ABIOMED, Inc. (NASDAQ ABMD) opened at 163.96 on Friday. The firm’s 50 day moving average price is $152.81 and its 200-day moving average price is $138.79. The stock has a market cap of $7.23 billion, a P/E ratio of 95.88 and a beta of 0.22. ABIOMED, Inc. has a 12-month low of $95.14 and a 12-month high of $164.60.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.03. The business had revenue of $132.47 million for the quarter, compared to analyst estimates of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The company’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same period last year, the company posted $0.29 earnings per share. Equities research analysts anticipate that ABIOMED, Inc. will post $2.24 earnings per share for the current fiscal year.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.